These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17366652)

  • 1. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes.
    Casini A; Mastrobuoni G; Ang WH; Gabbiani C; Pieraccini G; Moneti G; Dyson PJ; Messori L
    ChemMedChem; 2007 May; 2(5):631-5. PubMed ID: 17366652
    [No Abstract]   [Full Text] [Related]  

  • 2. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
    Meier SM; Hanif M; Kandioller W; Keppler BK; Hartinger CG
    J Inorg Biochem; 2012 Mar; 108():91-5. PubMed ID: 22420927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
    Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
    Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
    Nazarov AA; Risse J; Ang WH; Schmitt F; Zava O; Ruggi A; Groessl M; Scopelitti R; Juillerat-Jeanneret L; Hartinger CG; Dyson PJ
    Inorg Chem; 2012 Mar; 51(6):3633-9. PubMed ID: 22394115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
    Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
    Casini A; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
    Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
    ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CE in anticancer metallodrug research--an update.
    Hartinger CG; Keppler BK
    Electrophoresis; 2007 Oct; 28(19):3436-46. PubMed ID: 17847132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.
    Williams JP; Lough JA; Campuzano I; Richardson K; Sadler PJ
    Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3563-9. PubMed ID: 19844963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media.
    Nováková O; Nazarov AA; Hartinger CG; Keppler BK; Brabec V
    Biochem Pharmacol; 2009 Feb; 77(3):364-74. PubMed ID: 19014908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
    Groessl M; Hartinger CG; Dyson PJ; Keppler BK
    J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and differentiation of ruthenium(II) complexes with 1,4,7-trithiacyclononane and nitrogen heterocycles by electrospray mass spectrometry.
    Santana-Marques MG; Amado FM; Correia AJ; Lucena M; Madureira J; Goodfellow BJ; Félix V; Santos TM
    J Mass Spectrom; 2001 May; 36(5):529-37. PubMed ID: 11391809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based neutral ruthenium(II) arene complex: selective anticancer action.
    Wu CH; Wu DH; Liu X; Guoyiqibayi G; Guo DD; Lv G; Wang XM; Yan H; Jiang H; Lu ZH
    Inorg Chem; 2009 Mar; 48(6):2352-4. PubMed ID: 19220049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA structural distortions induced by ruthenium-arene anticancer compounds.
    Gossens C; Tavernelli I; Rothlisberger U
    J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
    Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
    J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.